Figure 2.

Effects of CB1R agonists on insulin secretion. A and B, Relative intracellular cAMP (A) and insulin (B) concentrations secreted from βTC6 cells treated with the synthetic CB1R agonist WIN55,212‐2 before the subsequent addition of Ex‐4. C, Effects of blocking CB1R on Ex‐4‐mediated insulin secretion in human islets. Human islets were pre‐treated with a CB1R inverse agonist AM251 before the subsequent addition of Ex‐4. D, Relative insulin concentrations secreted from βTC6 cells in response to glucose in the absence or presence of WIN55,212‐2, AM251 or both. E, Relative insulin concentrations secreted from human islets in response to glucose in the absence or presence of ACEA or 2‐AG. All values were normalized to protein concentration. Data are shown as the mean ± SEM from three independent experiments. *P < .05; **P < .01